Abstract
Chronic congestive heart failure has become a significant medical burden in the adult and a growing problem in the pediatric age group. While the etiologies of heart failure differ between children and adults, applied medical therapies are generally the same. In this regard, over the last decade, β-adrenergic receptor blockade has become an important component in drug therapy of congestive heart failure in the adult population. A third-generation β-blocker, carvedilol, has now been shown in adult trials to be efficacious in the treatment of heart failure and has been shown to be superior to other similarly used β-blockers. Carvedilol use has been adapted into pediatric heart failure practice although data supporting its efficacy in infants and children are scarce. This review will describe the application of carvedilol in the adult, as it pertains to pediatric practice, review the existing pediatric literature and describe our institutions experience with carvedilol in heart failure therapy.
Keywords: cAMP, Left ventricular (LV)reverse remodeling, pharmacokinetics, Beta blockers, transplantation
Cardiovascular & Hematological Disorders-Drug Targets
Title: The Use of Carvedilol in Pediatric Heart Failure
Volume: 6 Issue: 1
Author(s): S. C. Greenway and L. N. Benson
Affiliation:
Keywords: cAMP, Left ventricular (LV)reverse remodeling, pharmacokinetics, Beta blockers, transplantation
Abstract: Chronic congestive heart failure has become a significant medical burden in the adult and a growing problem in the pediatric age group. While the etiologies of heart failure differ between children and adults, applied medical therapies are generally the same. In this regard, over the last decade, β-adrenergic receptor blockade has become an important component in drug therapy of congestive heart failure in the adult population. A third-generation β-blocker, carvedilol, has now been shown in adult trials to be efficacious in the treatment of heart failure and has been shown to be superior to other similarly used β-blockers. Carvedilol use has been adapted into pediatric heart failure practice although data supporting its efficacy in infants and children are scarce. This review will describe the application of carvedilol in the adult, as it pertains to pediatric practice, review the existing pediatric literature and describe our institutions experience with carvedilol in heart failure therapy.
Export Options
About this article
Cite this article as:
Greenway C. S. and Benson N. L., The Use of Carvedilol in Pediatric Heart Failure, Cardiovascular & Hematological Disorders-Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/187152906776092686
DOI https://dx.doi.org/10.2174/187152906776092686 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Treatment of Hypertension in Chronic Kidney Disease: Does one Size Fit All? A Narrative Review from a Nephrologist’s Perspective
Current Hypertension Reviews Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders